← Eichor
Condition: Tumor Infiltrating Lymphocyte Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Tumor Infiltrating Lymphocyte

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
Phase 1 · 1 location(s) · David Bartlett, MD · NCT07192900Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06530303Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours
NA · 3 location(s) · Grit Biotechnology · NCT06397963TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemo
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07330037A Study of GC101 TIL in Advanced Solid Tumors (TR)
EARLY_Phase 1 · 1 location(s) · Shanghai Juncell Therapeutics · NCT04967833A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06863233TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients
Phase 2 · 1 location(s) · University Hospital, Basel, Switzerland · NCT06455917Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer
NA · 1 location(s) · Grit Biotechnology · NCT06819280T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Phase 1 · 1 location(s) · Inge Marie Svane · NCT06783270The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes
Phase N/A · 1 location(s) · Changzhi People's Hospital Affiliated to Changzhi Medical Co · NCT07069842Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (
EARLY_Phase 1 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT05141474Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06961357A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06598371Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tu
Phase 2 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT06630611Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06047977The Lymphocytic Infiltrate of Lung Tumors.
Phase N/A · 1 location(s) · Scientific Institute San Raffaele · NCT06470607Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1/Phase 2 · 10 location(s) · Obsidian Therapeutics, Inc. · NCT06060613Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
Phase 2 · 44 location(s) · UNICANCER · NCT06078384Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
Phase 1/Phase 2 · 4 location(s) · Fundacio Clinic Barcelona · NCT05451784A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiat
Phase 1 · 2 location(s) · Memorial Sloan Kettering Cancer Center · NCT05607095T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT02133196A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Met
Phase 1/Phase 2 · 11 location(s) · Iovance Biotherapeutics, Inc. · NCT05361174Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Sol
EARLY_Phase 1 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07349160TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06538012A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
Phase 2 · 5 location(s) · Suzhou BlueHorse Therapeutics Co., Ltd. · NCT07444437Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
Phase 1 · 1 location(s) · Allegheny Singer Research Institute (also known as Allegheny · NCT07443020A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
EARLY_Phase 1 · 1 location(s) · Shanghai Juncell Therapeutics · NCT05142475Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Phase 2 · 1 location(s) · Dan Zandberg · NCT06052839A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)
EARLY_Phase 1 · 1 location(s) · Shanghai Juncell Therapeutics · NCT05098171A Phase II Trial of LM103 in Advanced Melanoma
Phase 2 · 13 location(s) · Suzhou BlueHorse Therapeutics Co., Ltd. · NCT07310784
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.